RBCL OTC
RBC Life Sciences, Inc.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +75.0%
1Y: +600.0%
3Y: +40.0%
5Y: -99.4%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$26M
+5.8% ▲
5Y CAGR: -2.0%
Gross Profit
$14M
+1.1% ▲
5Y CAGR: -1.0%
Operating Income
-$666K
+73.5% ▲
Net Income
-$756K
-1.9% ▼
EPS (Diluted)
$-0.34
+0.0% ▲
EBITDA
-$252K
+16.8% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|---|---|---|---|---|
| Revenue | $25M | $25M | $28M | $24M | $26M |
| YoY Growth | -11.6% | +1.2% | +11.0% | -13.8% | +5.8% |
| Cost of Revenue | $13M | $13M | $13M | $11M | $12M |
| Gross Profit | $13M | $12M | $16M | $13M | $14M |
| Gross Margin | 50.2% | 47.2% | 55.3% | 55.2% | 52.8% |
| R&D Expenses | $0 | $0 | $0 | $0 | $0 |
| SG&A Expenses | $13M | $12M | $16M | $15M | $14M |
| Operating Expenses | $13M | $13M | $16M | $16M | $14M |
| Operating Income | -$464K | -$625K | -$625K | -$3M | -$666K |
| Operating Margin | -1.8% | -2.5% | -2.2% | -10.3% | -2.6% |
| Interest Expense | $126K | $112K | $96K | $42K | $0 |
| Income Before Tax | -$590K | -$736K | -$721K | -$846K | -$666K |
| Tax Expense | -$228K | -$236K | -$118K | -$104K | $90K |
| Net Income | -$361K | -$500K | -$603K | -$742K | -$756K |
| Net Margin | -1.4% | -2.0% | -2.1% | -3.0% | -2.9% |
| EPS (Diluted) | $-0.16 | $-0.23 | $-0.27 | $-0.34 | $-0.34 |
| EBITDA | $121K | -$36K | -$45K | -$302K | -$252K |
| Shares Outstanding | 2M | 2M | 2M | 2M | 2M |